Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 8

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 8
---
 worldwide as a form of radiation
    therapy due to its unique beam shaping characteristics. As a result, this new technology offers a major opportunity for Shuttle Pharma
    to strive to develop an innovative and well-tolerated drug for proton therapy sensitization.

    ●
    Execute
    a disciplined business development strategy to strengthen our portfolio of product candidates. We have built our current product
    pipeline through in-house discovery, development, partnerships with leading academic institutions and through in-licensing. We will
    continue to evaluate new in-licensing opportunities and collaboration agreements with leading academic institutions and other biotechnology
    companies around programs that seek to address areas of high unmet need and for which we believe there is a high probability of clinical
    success, including programs beyond our target franchise areas and current technology footprint.

    ●
    Invest
    in our HDAC platform technology and maximize its utility across cancer therapies. We are initially applying the platform to develop
    drugs for cancer radiation sensitization, normal tissue radiation protection and post radiation immune stimulation. Based on the
    data we have obtained thus far, these drugs are immune regulatory. We intend to invest to develop other properties of our platform
    technology, as well.

    ●
    Enter
    into collaborations to realize the full potential of our platform. The breadth of our HDAC technology platform enables other
    therapeutic applications, including radiation sensitization and immune therapy. We intend to seek collaborations centered on our
    platform to maximize applications for cancer treatment.

    ●
    Establish
    Shuttle Diagnostics, Inc. as a subsidiary of SHPH to advance development of the predictive biomarker (PC-RAD Test) and the PSMA
    ligand (PSMA-B) to advance prostate cancer treatment.

8

Radiation
Therapy

Radiation
Oncologists use Radiation Therapy (RT) to treat cancers that cannot be completely removed by surgery but have not yet spread to distant
sites within the body. RT has been a mainstay for the treatment of cancer malignancies for more than half a century. The combination
treatment of radiation therapy and chemotherapy has involved the use of cytotoxic drugs, targeted biologic agents and targeted external
beam radiation to increase the destruction of tumor cells and cure or delay cancer progression. The low number of drugs and biologic
agents under investigation as radiation sensitizing agents highlights an unmet need for new approaches and agents that provide greater
effectiveness, increased quality and better tolerability for patients.

Currently